Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial
Invasive breast cancer: can surgery be eliminated after neoadjuvant systemic chemotherapy?
Phase II data report a pathologic complete response in patients who received radiotherapy after neoadjuvant therapy without surgery, when selected by image-guided vacuum-assisted core biopsy
Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer